Curriculum vitae personal history name


B. Invited Reviews and Editorials



Download 203.61 Kb.
Page5/5
Date31.01.2017
Size203.61 Kb.
#12890
1   2   3   4   5

B. Invited Reviews and Editorials


1. Campbell TB, Schooley RT. Therapy of human immunodeficiency virus type 1 infection with zidovudine and nonnucleosides. HIV: Advances in Research and Therapy. 1993;3:23-29.
2. Campbell TB. New antiretroviral agents for therapy of human immunodeficiency virus infection. Current Opinion Infect Dis. 1993;6:768-772.
3. Campbell TB, Sullenger, BA. Alternative approaches for the application of ribozymes as gene therapies for retroviral infections. Advances in Pharmacology 1995;33:143-178.
4. Campbell TB, Katzenstein D. Antiretroviral Rounds. Resistance: How do you know if you don't know? Antiretroviral Rounds. AIDS Clin Care 2005;17.
5. Flanigan TP, Campbell T, Harwell J, and Kumarasamy N. The extraordinary hope of antiretroviral therapy in South Africa (Even for patients with tuberculosis or Kaposi sarcoma!). J Infect Dis 2005;191:321-323.
6. Connick E, MaWhinney S, Wilson CC, Campbell TB. Challenges in the study of HIV-1 seroconverters. Clin Infect Dis 2005;40:1355-1357.
7. Campbell TB. Are all HIV-1 created equal? Clin Infect Dis 2006;42:853-854.
8. Campbell TB. Choice of an initial antiretroviral regimen in the resource-limited setting: the cost of virological failure. Clin Infect Dis 2008;43:723-725.
C. Other Publications

1. Campbell TB. Light induced division and genomic synchrony in Rhodopseudomonas sphaeroides. Texas A&M University. Senior Honors Thesis, 1980.


2. Campbell TB. Light mediated regulation of cellular growth and intracytoplasmic membrane assembly in phototropically growing cultures of Rhodopseudomonas sphaeroides. Texas A&M University. Master of Science Thesis, 1981.
D. Peer-Reviewed Abstracts

1. Campbell TB, Lueking DR. Light induced division and genomic synchronization of photoheterotropically growing cultures of Rhodopseudomonas sphaeroides. Annual meeting of the American Society of Biological Chemists, New Orleans, 1980.


2. Campbell TB, Lueking DR. Long chain fatty acid assimilation by Rhodopseudomonas sphaeroides. Annual meeting of the American Society for Microbiology, Atlanta, 1981.
3. Campbell TB, Lueking DR. Light mediated regulation of phospholipid synthesis in

Rhodopseudomonas sphaeroides. Annual meeting of the American Society of Biological Chemists, New Orleans, 1981.
4. Campbell TB, Young RK, Tarpley WG, Kuritzkes DR. Synergistic effect of U-87201E in combination with zidovudine against ZDV-resistant HIV-1 isolates [Abstract PoA2300]. VIIIth International Conference on AIDS, Amsterdam, 1992.
5. Campbell TB, Kuritzkes DR, Rosandich M, Bakhtiari M, Schooley RT, and the ACTG 184 Study Team. Delayed emergence of resistance to L-697,661 in patients with prior or concomitant zidovudine therapy. HIV Drug Resistance Second International Workshop, Noordwik, 1993.
6. Campbell TB, Routh JA, Bakhtiari M, Schooley RT, Kuritzkes DR. Detection of genotypic changes in reverse transcriptase during combination therapy with zidovudine and L-697,661 [Abstract Po- A26-0630]. IXth International Conference on AIDS, Berlin, 1993.
7. Campbell TB, Cech TR. Identification of ribozymes within a ribozyme library that efficiently cleave a long human immunodeficiency virus type-1 vif-vpr RNA in vitro. Novel HIV Therapies: From Discovery to Clinical Proof-of-Concept, SPIRAT/NCDDG Conference, Bethesda, 1995.
8. Campbell TB, Cech TR. Identification and characterization of catalytically active trans-cleaving ribozymes present within a library of ribozyme mutants. RNA '96. The First Annual Meeting of the RNA Society, Madison, 1996.
9. Campbell TB, McDonald CK, Hagen M. Effect of secondary structure within a long target RNA on ribozyme cleavage site accessibility. RNA '97. The Second Annual Meeting of the RNA Society, Banff, 1997.
10. Gray EA, McDonald CK, Campbell TB. The secondary structure of an RNA that contains HIV-1 nef. RNA '97. The Second Annual Meeting of the RNA Society, Banff, 1997.
11. Campbell TB, McDonald CK, Hagen M. The effect of secondary structure in a long substrate RNA on ribozyme cleavage efficiency. Tenth Annual Colorado Biotechnology Symposium, Boulder, 1997.
12. Campbell T, Rosandich M, Bakhtiari M, Shugarts D, Mitchell D, King J, Kuritzkes D, Ambruso D, Mladenovic J, Miles S, Pomerantz R, Schooley R, and the ACTG 285 Team. The effect of stem cell mobilization with filgrastim (rG-CSF) on viral replication in persons with HIV-1 infection. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, 1998.
13. McDonald CK, Gray EA, McSwiggen JA, Campbell TB. The effect of structure in HIV-1 nef RNA on the antiviral activity of ribozymes targeted to sites in nef. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, 1998.
14. Lee NS, Campbell TB, Rossi JJ. Identification of hammerhead ribozyme cleavage sites for RBE aptamer mediated ribozyme co-localization with HIV-1 env RNA. RNA '98. The Third Annual Meeting of the RNA Society, Madison, 1998.
15. Fitzpatrick L, Zhang X, Schooley RT, Campbell TB. Human herpesvirus 8 (HHV-8 or KSHV) is common in human immunodeficiency type-1 infected adults in Colorado. First Annual Meeting on Kaposi's Sarcoma Associated Herpesvirus and Related agents. Santa Cruz, 1998.
16. Schooley R, Mladenovic J, Campbell T, Pomerantz R, Miles S, Wong R, Landay A. ACTG 285: G-CSF (Filgrastim) for mobilization of CD34+ cells from the bone marrow of HIV-1 infected persons. 12th World AIDS Conference, Geneva, 1998.
17. Mladenovic J, Sevin A, Chiu S, Miles SA, Pomerantz R, Campbell TB, Bell D, Ambruso D, Wong R, Landay A, Coombs R, Schooley RT and the ACTG Study Team. Decreased mobilization of CD34+ cells in advanced HIV-1 disease: Results of a multicenter prospective study. Fortieth Annual Meeting of the American Society of Hematology, Miami Beach, 1998.
18. Fitzpatrick L, MaWhinney S, Zhang X.Q., Schooley RT, Campbell TB. HHV-8 (KSHV) viremia in HIV-1 infected persons. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
19. Campbell TB, Borok M, Gwanzura L, Fitzpatrick L, White IE, Ndemera B, Gudza I, MaWhinney S, Schooley RT. Relationship of peripheral blood KSHV virus load to Kaposi's sarcoma clinical stage and markers of HIV-1 infection. 2nd International Workshop on Kaposi's Sarcoma Associated Herpesvirus and Related Agents, Oxford, 1999.
20. White IE, Campbell TB. Quantitation of cell-free and cell-associated KSHV DNA by kinetic PCR. 2nd International Workshop on Kaposi's Sarcoma Associated Herpesvirus and Related Agents, Oxford, 1999.
21. Marble HA, Campbell TB. Changes in the polyadenylation state of the polyadenylated nuclear RNA of KSHV during viral lytic replication. 2nd International Workshop on Kaposi's Sarcoma Associated Herpesvirus and Related Agents, Oxford, 1999.
22. Campbell TB, Staskus KA, Evans R, White IE, Zhang XQ, Folkvord J, Connick E. Quantitative analysis of KSHV (HHV-8) virus load in plasma, PBMC, and lymph nodes from HIV-1-infected persons. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2000.
23. Connick E, Schlichtemeier R, Purner M, Schneider K, MaWhinney S, Campbell T, Kuritzkes D, Douglas J, Judson F, Schooley R. CCR5 heterozygosity is associated with preserved HIV-specific cellular immune responses in recent serconverters. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2000.
24. White IE, Borok M, Gudza I, Ndemera B, Rabinowitz I, Williams B, Gwanzura L, Campbell TB. Prevalence of KSHV DNA in the plasma of HIV-infected men. 3rd International KSHV Workshop, Amherst, 2000.
25. Campbell TB, Staskus KA, Evans R, White IE, Zhang XQ, Folkvord J, Connick E. KSHV replication in the lymph nodes of HIV-infected persons. 3rd International KSHV Workshop, Amherst, 2000.
26. White IE, Borok M, Gudza I, Ndemera B, Taziwa AT, Gwanzura L, Campbell TB. Relationship of plasma KSHV DNA and KS disease. 4th International Workshop on KSHV and Related Agents, Santa Cruz, 2001.
27. Hagen M, Campbell TB. Structural mapping of PAN RNA. 4th International Workshop on KSHV and Related Agents, Santa Cruz, 2001.
28. Rapaport E, Kuritzkes DR, Schooley RT, Campbell TB. Activation of an HIV-1 Reservoir During Hematopoietic Progenitor Cell Mobilization. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, 2002.
29. Connick E, Kocsis K, Campbell TB. The relationship of steady-state plasma HIV-1 RNA concentration and ex vivo HIV-1 replication rate. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, 2002.
30. Campbell TB, Young RK, Johnson SC, Lanier ER, Kuritzkes. Antiviral activity of lamivudine in persons infected with HIV-1 that has M184V and multiple thymidine analog mutations. XII International HIV Drug Resistance Workshop, Los Cabos, 2003.
31. Rapaport E, Mclean C, Campbell TB. Stimulation of HIV-1 replication in monocytoid cells by filgrastim. 11th Conference on Retrovirus and Opportunistic Infections, San Francisco, 2004.
32. Benson CA, Campbell T, MaWhinney S, Connick E, Forster J, Ray G, Thompson M, LandayA, Badaro R, Netto E, Judson F, Pallela6 F, Schooley R. A pilot open-label phase II trial of the safety and efficacy of a compact 3-drug antiretroviral treatment regimen for subjects with acute or recent primary HIV-1 infection. 12th Conference on Retrovirus and Opportunistic Infections, Boston, 2005.
33. Gripshover B, Santana J, Ribaudo H, Gerber J, Campbell T, Hogg E, Jarocki B, Hammer S, and Kuritzkes D. A randomized, placebo-controlled trial of amdoxovir vs placebo with enfuvirtide plus optimized background therapy for HIV-infected subjects failing current therapy (AACTG 5118). 12th Conference on Retrovirus and Opportunistic Infections, Boston, 2005.
34. Barbour JD, Hecht FM, Markowitz M, Little SJ, Daar ES, Kelleher A, Routy JP, Campbell T, Rosenberg E, Schafer K, Wood K, Segal M, Weidler J, Bates M, Grant RM. Greater CD4+ T Cell Rate of Gain During Anti-Retroviral Therapy Is Associated with Lower Pre-Treatment Viral pol Replication Capacity Independent of Virologic Response. The 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, 2005. Abstract WePe8.4B04.
34. Boritz E, Rapaport E, Campbell T, Koeppe J, Wilson C. CD4+ T-cell targeting of HIV-1 peptide sequences present in vivo during chronic, progressive HIV-1 disease. 13th Conference on Retroviruses and Opportunistic Infections, Denver, 2006.
35. White T, Hagen M, Gudza I, Ndemera B, White I, Borok M, Campbell T. Genetic diversity of Kaposi’s sarcoma herpesvirus in Zimbabwe. 13th Conference on Retroviruses and Opportunistic Infections, Denver, 2006.
36. Borok M, Ndemera B, Gudza I, Gwanzura L, Campbell T. Kaposi’s sarcoma-associated herpesvirus infection is uncommon among Zimbabwean blood donors. 13th Conference on Retroviruses and Opportunistic Infections, Denver, 2006.
37. Meditz A, Borok M, Gudza I, Gwanzura L, Ndemera B, Campbell T. Is there sex discrimination in AIDS-associated Kaposi’s sarcoma? 13th Conference on Retroviruses and Opportunistic Infections, Denver, 2006.
38. Gwanzura L, Ndemera B, Fiorillo SP, White IE, Zhang XQ, Machekano R, Katzenstein D, Borok M, Campbell TB. Comparison of Risks Factors for Human Herpesvirus 8 and Human Immunodeficiency Virus Type 1 in Urban African Men. XVI International AIDS Conference

Toronto, 2006.


39. Borok M, Gudza I, Fiorillo S, Ndemera B, Putnam B, Loeliger E, Gwanzura L, Schooley R, Campbell T. Improved Survival of AIDS-KS Treated with Co-formulated Abacavir/Lamivudine/Zidovudine in Zimbabwe. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, 2007.
40. Borok M, Gudza I, Fiorillo S, Ndemera B, Putnam B, Loeliger E, Gwanzura L, Schooley R, Campbell T. A 48 week efficacy and safety analysis of treatment of AIDS-KS with co-formulated ABC/3TC/ZDV in Zimbabwe. African International Conference on Immunity, Victoria Falls, 2007.
41. Gwanzura L, Ndemera B, Fiorillo SP, White IE, Zhang XQ, Machekano R, Katzenstein D, Borok M, Campbell TB. Seroprevalence and risk factors for HHV-8 Infection in Zimbabwe. African International Conference on Immunity, Victoria Falls, 2007.
42. Katlama C, Campbell T, Clotet B, Johnson M, Lazzarin A, Towner W, Trottier B, Peeters M, Vingerhoets J, De Smedt G, Baeten B, Beets G, Sinha R, Woodfall B on behalf of the DUET-2 study group. DUET-2: 24 week results of a randomised double-blind trial to evaluate the efficacy and safety of TMC125 versus placebo in 591 treatment-experienced HIV-1 infected patients. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, 2007
43. Campbell T, Mills A, Morlat P, Schechter M, De Smedt G, Peeters M, Tomaka F, Woodfall B. TMC125 safety and tolerability in treatment-experienced hepatitis B or C co-infected patients in DUET-1 and DUET-2. HepDART, Maui, 2007
44. Johnson M, Campbell T, Clotet B, Katlama C, Lazzarin A, Towner W, Peeters M, Vingerhoets J, Bollen S, De Smedt G on behalf of the DUET-2 study group. DUET-2:Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 591 treatment-experienced HIV-1-infected patients. 15th Conference on Retroviruses and Opportunistic Infections, Boston, 2008.
45. Robertson K, Kumwenda J, Supparatpinyo K, Evans S, Jiang H, Campbell T and the 5199 study team. Baseline Data from ACTG 5199: The International Neurological Study. 15th Conference on Retroviruses and Opportunistic Infections, Boston, 2008.
46. Grinsztejn B, Smeaton L, De Gruttola V, Barnett R, Currier J, Swann E, Hakim J, Flanigan T, Kumarasamy N, Campbell T for the PEARLS Study Team of the ACTG. Gender-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world depend on CD4+ lymphocyte count. 15th Conference on Retroviruses and Opportunistic Infections, Boston, 2008.
47. Andrade A, Smeaton L, Campbell T, Bollinger R, Mitsuyasu R, Lama J, Klingman K, Hakim J, Kumarasamy N, Gupta A, for the PEARLS study team of the ACTG. Baseline correlates of pre-antiretrovial therapy nutritional status among HIV-infected adults in diverse regions of the world. XVII International AIDS Conference Mexico City, 2008.
48. Katlama K, Campbell T, Schechter M, Peeters M, Bicer C, Sinha R, Leopold L, De Smedt G. Incidence and severity of nervous system and psychiatric events are similar with etravirine (ETR, TMC125) versus placebo: pooled 48-week data from the phase III DUET studies. XVII International AIDS Conference Mexico City, 2008.
49. Firnhaber C, Smeaton L, Hakim J, De Gruttola V, Swann E, Flannigan T, Kumarasamy N, Campbell T, for the PEARLS Study Team of the ACTG. The strength of the correlation between total lymphocyte count and CD4+ lymphocyte count varies in diverse areas of the world. XVII International AIDS Conference Mexico City, 2008.
50. Gwanzura L, Samaneka L, Mudzviti E, Mutimuri M, Mugutso A, Ndemera B, Taziwa A, Mandozana G, Tinago W, Samaneka W, Hakim J, Borok M, Campbell T, Connick E. Identification and presentation of primary HIV-1 infection in Zimbabwe. XVII International AIDS Conference Mexico City, 2008.
51. Borok M, Gudza I, Fiorillo S, Ndemera B, Fernandez G, Putnam B, Loeschel E, Gwanzura L, Schooley R, Campbell T. A pilot study of the effects of highly active antiretroviral therapy on Kaposi’s sarcoma in Zimbabwe. XVII International AIDS Conference Mexico City, 2008.
52. Safren S, Celentano D, Smeaton L, Hendriksen E, Hosseinipour M, Barnett R, Guanira J, Flanigan T, Kumarasamy N, Klingman K, Swann E, De Gruttola V, Campbell T for the PEARLS Study Team. Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world. XVII International AIDS Conference Mexico City, 2008.
53. Campbell T, Smeaton L, De Gruttola V, Hakim J, Kumarasamy N, Flanigan T, Klingman K, Martinez A, Berendes S, Cardoso S, Firnhaber C, Hosseinipour M, Joglekar A, Mngqibisa R, Rivière C, Sanchez J, Santos B, Supparatpinyo K, Nair A, Walawander A, Hosey L, Moran L, Barnett R, Swann E, Loeschel E, Pakes G, Piliero P, Rooney J, Snowden W, Thal G, Uy J, Andrade A, Currier J, Eron J, Eshleman S, Fiscus S, Gulick R, Haas D, Hammer S, Mitsuyasu R, and Schooley R, for the PEARLS study team of the ACTG. PEARLS (ACTG A175): A multinational study of didanosine-EC, emtricitabine and atazanavir vs. co-formulated zidovudine/lamivudine and efavirenz for initial treatment of HIV-1 infection. XVII International AIDS Conference Mexico City, 2008.
54. Campbell T, Peeters M, Nijs S, Kakuda T, Witek J, De Smedt G. Safety and tolerability of etravirine, a newly approved NNRTI for the management of treatment-experienced patients with HIV, in patients co-infected with hepatitis B or C virus. National Conference on Correctional Health Care, Chicago, 2008.
55. Navia B, Harezlak J, Buchthal S, Cohen R, Taylor M, Schifitto G, Singer E, Campbell T, Daar E, Yiannoutsos C and the HIV Neuroimaging Consortium. Persistence of HIV-related Brain Injury in the HAART Era: A Multicenter Proton Magnetic Resonance Spectroscopy Study. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, 2009.
56. Robertson K, Jiang H, Tripathy S, Santos B, Silva M, Montano S, Kanyama C, Firnhaber C, Evans S, Campbell T, and the ACTG 5199 Team. Improved Neuropsychological Function during HAART in Diverse Resource-limited Settings: AIDS Clinical Trials Group Study A5199, the International Neurological Study. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, 2009.
57. Gwanzura L, Samaneka L, Samaneka W, Mudzviti1 E, Mutimuri M, Taziwa A, Ndemera B, Tinago W, Mandozana G, Hakim J, Borok M, Campbell T, Barron M, Connick E. Identification and presentation of primary HIV-1 infection in Harare, Zimbabwe. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, 2009.
59. Campbell T, Grinsztejn B, Hartikainen J, Nijs S, Witek J. Long-term safety profile of etravirine in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the phase III DUET trials. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, 2009.
60. Andrade A, Rosenkranz S, Daar E, Jacobson J, Acosta E5, Lederman M, Town J, Campbell T, Mellors J, Kuritzkes D for the ACTG 5248 team. Longer phase I viral decay in treatment-naïve patients receiving raltegravir-based ART: Preliminary results from ACTG 5248. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2010.
61. Thio C, Smeaton L, Saulynas M, Hwang H, Kumarasamy N, Flanigan T, Hakim J, Amod F, Campbell T, Currier J and the PEARLS/A5175 and OCTANE/A5208 Study Teams for the ACTG. Characterization of hepatitis B virus (HBV) and its association with HIV in an antiretroviral therapy (ART)-naïve, multi-national cohort from 2 randomized controlled trials (RCT) of the AIDS Clinical Trials Group (ACTG). 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2010.
62. Nelson BC, Borok MB, Makadzange T, Mhlanga T, Campbell TB. AIDS-related Kaposi’s sarcoma: Outcomes after initiation of highly active antiretroviral therapy under routine conditions in Zimbabwe. The 12th International Conference on Malignancy in AIDS and Other Acquired Immunodeficiencies, Bethesda, MD, 2010.
63. Borok MZ, Fiorillo S, Gudza I, Ndemera B, Putnam B, Watson H, Wegzyn C, Gwanzura L, Campbell T. A pilot study of co-formulated abacavir/lamivudine/zidovudine versus coformulated abacavir/lamivudine plus co-formulated lopinavir/ritonavir for treatment of refractory AIDS-KS in an African setting. XVIII International AIDS Conference, Vienna, 2010.
64. Castillo-Mancilla J, Allshouse A, Collins C, Hastings-Tolsma M, Campbell T, MaWhinney S. Differences in sexual risk behavior and HIV/AIDS risk factors among foreign born and US-born Hispanic women in the United States. XVIII International AIDS Conference, Vienna, 2010.
65. Andrade A, Baheti G, Smeaton L, Brundage RC, Kumarasamy N, Flanigan T, Hakim J, Braun K, Campbell T, Fletcher CV and the AIDS Clinical Trials Group (ACTG) PEARLS Study. Sex- and geographic-based differences in atazanavir (ATV) pharmacokinetics (PK) in subjects treated with didanosine (ddI-EC), emtricitabine (FTC), and ATV in the AIDS Clinical Trials Group (ACTG) Prospective Evaluation of Antiretrovirals in Resource Limited Settings (PEARLS) Study. 18th Conference on Retroviruses and Opportunistic Infections, Boston, 2011.
66. Robertson K., Jiang H., Kumwenda J., Supparatpinyo K., Evans S., Campbell T., Price R., Tripathy S., Kumarasamy N., LaRosa A. A comparison of neuropsychological and neurological effects of three antiretroviral regimens in diverse resource limited settings: AIDS clinical trials group study A5199, the international neurological study. 18th Conference on Retroviruses and Opportunistic Infections, Boston, 2011.
67. Cohen R, Harezlak J, Gongvatana A, Schifitto G, Taylor M, Singer E, Campbell T, Daar E, Yiannoutsos C, Navia B, and HIV Neuroimaging Consortium. Conversion to HIV-associated Neurocognitive Disorder. 18th Conference on Retroviruses and Opportunistic Infections, Boston, 2011.
68. Letang E, Lewis J, Bower M, Borok M, Mosam A, Campbell T, Naniche D, Newsom-Davis T, Shaik F, Fiorillo S, Macete E, Schellenberg D, Easterbrook PJ. Incidence and Predictors of Kaposi’s Sarcoma associated with Immune Reconstitution Inflammatory Syndrome in sub-Saharan Africa and the UK. 18th Conference on Retroviruses and Opportunistic Infections, Boston, 2011.
69. Campbell T, Smeaton L, Kumarasamy N, Flanigan T, Sanchez J, Grinsztejn B, Tripathy S, Kumwenda J, DeGruttola V, Hakim J and the ACTG PEARLS (A5175) Study Team. Efficacy and safety of efavirenz (EFV) with either co-formulated lamivudine/zidovudine (3TC/ZDV) or emtricitabine/tenofovir-DF (FTC/TDF) for initial treatment of HIV-1 infected men and women in diverse multinational settings. 18th Conference on Retroviruses and Opportunistic Infections, Boston, 2011.

E. Manuscripts Under Review

1. Cohen RA, Harezlak J, Bucthal, S, Schifitto G, Gongvatana A, Clark U, Paul R, Taylor M, Thompson P, Tate D, Algers J, Brown M, Zhong J, Campbell T, Singer E, McMahon D, Tso Y, Yiannoutsos CT, Navia B and the HIV Neuroimaging Consortium. Cerebral metabolite abnormalities in HIV are associated with cortical and subcortical volumes.


2. Harezlak J, Yiannoutsos CT, Buchthal S, Taylor M, Schifitto G, Zhong J, Daar E, Alger J, Brown M, Singer E, Campbell T, McMahon D, Tso Yuen, Matesan J, Shirley Paulose, Michelle Gaugh, Christine Tripoli, Sally Canmann, Cohen R, Navia BA and the HIV Neuroimaging Consortium. Pathological anatomy of the AIDS dementia complex in the era of combination antiretroviral therapies: A proton magnetic resonance spectroscopy study.
3. Girard P-M, Campbell T, Grinsztejn B, Hartikainen J,Rachline A,Nijs S, Witek J. Pooled 96-week results of the Phase III DUET-1 and DUET-2 trials of etravirine: analysis of adverse events and laboratory abnormalities of special interest.
4. Campbell TB, Smeaton L, De Gruttola V, Eshleman SH, Klingman K, Martinez A, Grinsztejn B, Hosseinipour M, Kumwenda J, Lalloo U, Reverie C, Sanchez J, Firnhaber C, Santos BR, Supparatpinyo K, Tripathy T, Moran L, Safren S, Snoden W, Petrella L, Rooney JF, Uy J, Schooley RT, Flanigan T, Kumarasamy N, Hakim J for the PEARLS study team of the ACTG. A Randomized Clinical Trial of the Efficacy and Safety of Once-Daily Antiretroviral Regimens in Diverse Multinational Settings.
5. Cohen RA, Harezlak J, Schifitto G, Taylor M, Heaton , Robertson K, Daar ES, Campbell TB, Singer E, Buchthal S, Alger J, McMahon D, Tso Y, Gongvatana A, Yiannoutsos CT, Navia B and the HIV Neuroimaging Consortium. Conversion to AIDS Dementia Complex and Associated Predictors in the Era of Combined Antiretroviral Therapies.
6. Gongvatana A, Harezlak J, Buchthal S, Daar ES, Schifitto G, Campbell TB, Taylor M, Singer E, Algers J, Zhong J, Brown M, McMahon D, Tso Y, Mi D, Heaton R, Robertson K, Yiannoutsos C, Cohen RA, Navia B and the HIV Neuroimaging Consortium. Progressive Cerebral Injury in the Setting of Chronic HIV infection and Antiretroviral Therapies.
7. Nielsen-Saines K, Komarow L, Cu-Uvin S, Jourdain G, Klingman K, Shapiro D, Mofenson L, Moran L, Campbell TB, Hitti J, Currier J for the A5190/P1054 Study Team. Assessment of Safety and Toxicity Following Maternal Antiretroviral Exposure in Infants Born To HIV-Infected Women Enrolled in Antiretroviral Treatment Protocols in Diverse Areas of the World. Eighteen Month Results of AIDS Clinical Trials Group (ACTG) Study 5190/ Pediatric AIDS Clinical Trials Group (PACTG) 1054.
8. Cohen R, Harezlak J, Taylor M, Buchthal S, Schifitto G, Zhong J, Daar ES, Alger J, Brown M, Singer E, Campbell T, McMahon D, So YT, Yiannoutsos CT, Navia BA and the HIV Neuroimaging Consortium. Predictors of CNS Injury as Measured by Proton Magnetic Resonance Spectroscopy in the Setting of Chronic HIV infection and CART.
9. Nelson BC, Borok MZ, Ndhlovu CE, Mhlanga T, Makadzange T, Campbell TB. AIDS-Associated Kaposi’s Sarcoma: Outcomes after Initiation of Antiretroviral Therapy at a University-affiliated Hospital in Urban Zimbabwe.
10. Erlandson KM, Allshouse A, Jankowski C, Duong S, MaWhinney S, Kohrt WM, Campbell TB. A Simultaneous Comparison of Three Functional Status Assessments with the Veteran’s Aging Cohort Study Index in Virologically Suppressed HIV-Infected Adults.



Download 203.61 Kb.

Share with your friends:
1   2   3   4   5



The database is protected by copyright ©ininet.org 2024
send message
    Main page
american college